Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-06-03
1995-10-31
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514212, 514252, 514253, 514326, 540597, 540601, 544139, 544295, 544357, 544360, 544363, 544370, 546210, A61K 31535, A61K 31495, A61K 3155, C07D41300, C07D40300, C07D40100, C07D42100, C07D24102
Patent
active
054629403
ABSTRACT:
The 4-oxocyclic ureas and the pharmaceutically acceptable salts and esters thereof, of the present invention are useful as antiarrhythmic and antifibrillatory agents and have the following general structure: ##STR1## wherein X, Y, A, L, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined as in the specification.
REFERENCES:
patent: 3415821 (1968-12-01), Davis et al.
patent: 4393204 (1983-07-01), Pelosi, Jr.
patent: 4543359 (1985-09-01), Ellis et al.
patent: 4689341 (1987-08-01), Diamond et al.
patent: 4705799 (1987-11-01), Gregory
patent: 4707499 (1987-11-01), Baran et al.
patent: 4713382 (1987-12-01), Pascal
patent: 4720580 (1988-01-01), Buzby et al.
patent: 4775670 (1988-10-01), Sykes et al.
patent: 4804662 (1989-02-01), Nickisch et al.
patent: 4806536 (1989-02-01), Cross et al.
patent: 4851526 (1989-07-01), Greenberg et al.
patent: 4870095 (1989-09-01), Bailey
patent: 4876262 (1989-10-01), Oinuma et al.
patent: 4963561 (1990-10-01), Lesher et al.
patent: 4966967 (1990-10-01), Lumma, Jr. et al.
patent: 4994459 (1991-02-01), Butera et al.
Bigger, J. T. and Hoffman, B. F., "Antiarrhythmic Drugs", Ch. 35 in Goodman and Gilman's The Basis of Pharmaceutical Therapeutics, 8th ed., ed., A. G. Gilman, pp. 840-873 (1990).
Bigger, J. T., "Antiarrhythmic Treatment: An Overview", American Journal of Cardiology, vol. 53, pp. 8B-16B, Feb. 27, 1984.
Woosley, R. L., "Antiarrhythmic Agents", in the Heart, Ch. 95, pp. 1682-1711, ed. J. W. Hurst, New York, McGraw-Hill (1990).
Woosley, R. L., "Antiarrhythmic Drugs", Annual Review, Pharmacology and Toxicology, vol. 31, pp. 427-455 (1991).
Morganroth, J. and Bigger, J. T., "Pharmacological Management of Ventricular Arrhythmias After the Cardiac Arrhythmia Suppression Trail", American Journal of Cardiology, vol. 65, pp. 1497-1503 (1990).
Goldstein, S., "Toward a New Understanding of the Mechanism and Prevention of Sudden Death in Coronary Heart Disease", Circulation, vol. 82(1):pp. 284-288 (1990).
Echt, D. S. et al. "Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trail", New England Journal of Medicine, vol. 324, pp. 781-788 (1991).
Coplen, S. E. et al. "Efficacy and Safety of Quinidine Therapy for Maintenance of Sinus Rhythm After Cardioverison: A Meta-analysis" Circulation, vol. 82, pp. 1106-1116 (1990).
Calcagno Mark A.
Pelosi, Jr. Stanford S.
Yu Chia-Nien
Clark Karen F.
Norwich Eaton Pharmaceuticals, Inc.
Rasser Jacobus C.
Suter David L.
Tsang Cecilia
LandOfFree
4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1772426